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ABSTRACT 
Linran Zhou: Research and Diagnostic Validity of Whole Exome Sequencing in Neuromuscular 
Disease 
(Under the direction of Jonathan S. Berg) 
 
Neuromuscular diseases (NMDs) are a broad group of inherited genetic disorders with a total 
global prevalence exceeding 1 in 3,000. Affecting the muscle and peripheral nervous system, 
NMDs result in significant disability and despite increased understanding of their molecular 
basis, the cause is unknown in the majority of patients. In an NCGENES patient cohort, we 
examined the diagnostic yield of whole exome sequencing (WES) for variants in genes currently 
associated with NMDs, neuropathies, and myopathies, and we evaluated the literature for known 
information about these genes. We analyzed the variants from WES in genes not on the current 
diagnostic lists to search for novel, rare, deleterious variants in possible disease candidate genes 
and identify patient candidates for further molecular analysis. Based on literature and clinical 
reports, we also evaluated the construction of the current diagnostic lists, expanding the 
myopathy and neuropathy lists by over 80 genes each. The lists were curated so that NMD list 
encompassed all myopathy and neuropathy genes, while the myopathy and neuropathy lists 
remained as unique as possible. Based on our overall analysis, we constructed a schematic to aid 
clinicians in deciding when to apply WES for patients with a neuromuscular condition of 
suspected genetic etiology.  
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INTRODUCTION 
 Neuromuscular diseases (NMDs) are a broad category of genetic disorders that affect 
both the muscle and the peripheral nervous system. Consequently, they principally affect the 
ability to perform voluntary movements, leading to significant disability and morbidity in both 
children and adults.
1
 NMDs consist of over 200 monogenic disorders, which include disorders 
like Duchenne muscular dystrophy (DMD), amyotrophic lateral sclerosis, limb-girdle muscular 
dystrophies (LGMDs) and hereditary motor and sensory neuropathies. Analysis of reported 
studies suggests that roughly 1 in 3,500 individuals across both sexes in the global population 
could be expected to present with an inherited NMD in childhood or later life. If rarer NMDs are 
also included in the analysis, it is estimated that the overall global prevalence could exceed 1 in 
3,000, highlighting the need for research and development in this area.
1,2
 NMDs range in time of 
onset from in utero to old age, but to a large extent, they first present in infancy, childhood, or 
adolescence.
3
 
 Over the past 25 years, there have been monumental research and clinical endeavors that 
have revealed much about the molecular bases of NMDs, catalyzed by the identification of many 
variants in genes and loci in people with the disorders and significant improvements in the 
treatment of symptoms and complications.
1,3
 Treatments such as assisted ventilation, 
physiotherapy, and orthotics have greatly increased the life expectancy and quality of life for 
many patients with NMDs.
3
 There are databases that catalogue the known genes and linked loci 
with genes not yet identified associated with NMDs (summarized in Figure 1.) 
2 
  
 
Figure 1.
3
 Categories of neuromuscular disorders, summarized from a November 2011 table published by the 
journal Neuromuscular Disorders. There are 16 categories of neuromuscular disorders. Taken from Laing, 2012. 
 
Despite this progress and mounting clinical and molecular evidence, the causes of NMDs 
remain unknown in a majority of patients. Major challenges that persist in attempting to link 
genetic variants to specific phenotypes in affected families or individuals include lack of 
segregation data, especially in sporadic cases, non-specific clinical features that could be 
indicative of multiple disorders, and genetic and phenotypic heterogeneity. Some genes 
associated with NMDs, such as TTN, DMD, or RYR, are among the largest human genes.
1
 
Combined with the sheer variety of variants in those known genes – point mutations and small 
indels, deletions of entire genes, deletion duplication of exons, among others – and the effects of 
unknown genes potentially associated with NMDs, these factors greatly complicate molecular 
and genetic analysis.
1
    
Recently, the use of next generation sequencing (NGS) techniques has become a popular 
and effective technique for massively parallel analysis of many genes and loci. These 
technologies have led to successful identification of several Mendelian disease genes, some of 
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which were not amenable to linkage analysis as a result of disease rarity and strong negative 
selection on causal mutations, leading to those mutations often arising from de novo events.
1,4
 
One key application of NGS technologies is whole exome sequencing (WES). 
The human genome consists of about 3.2 billion nucleotides and has about 23,500 genes. 
The protein-coding region of each gene is referred to as an exon, and the human genome 
contains about 180,000 exons. These exons are collectively referred to as the exome, which 
makes up about 1% of the human genome and represents the totality of all protein-coding 
regions. Although the exome does not include roughly 99% of the human genome, about three-
quarters of currently known pathogenic variants affect exons, so much of the focus in medically-
applicable sequencing is targeted towards the exome.
5
 Exome sequencing has demonstrated its 
value in many notable cases, such as when it was used to identify variants in DHODH as the 
cause of Miller disorder, a rare Mendelian disorder of previously unknown etiology.
6
 While 
thorough technical descriptions of exome sequencing can be found elsewhere
7,8
, the general 
process is as follows. First, DNA is extracted from white blood cells, sheared into fragments, 
hybridized to mRNA baits to enrich for exomic regions, and sequenced using various sequencing 
technologies. The NGS sequencing experiments quickly produce millions to billions of short 
sequence reads, which are aligned to the human reference genome. After mapping, a series of 
quality checks and processing steps are applied to minimize sequencing artifacts that could 
interfere with variant calling. Finally, variants in the sequenced samples are detected, annotated 
with useful biological information, and filtered to output a manageable list of candidate variants 
for experimental verification.
9,10
 As with any test, WES is not immune to false-positive and 
false-negative results, so the generated data must be carefully analyzed to be medically 
applicable. 
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This study is part of the larger, comprehensive North Carolina Clinical Genomic 
Evaluation by Next-Generation Exome Sequencing (NCGENES) project. As the costs of exome 
and genome sequencing decrease, there is increasing interest in clinical genome-scale analysis, 
and as a result, research is needed to understand the best practices. The four overarching aims of 
NCGENES are as follows: identify how WES performs as a diagnostic tool, learn how incidental 
findings affect patient choices and healthcare decisions, develop a practical and ethical clinical 
framework to incorporate WES data, and bring WES to medically-underserved groups to explore 
opportunities and challenges. Thus, the questions and objectives of this study reflected the 
overall aims of NCGENES. First, given the current diagnostic lists
I
 for NMDs, myopathy, and 
neuropathy, we were interested in the diagnostic yield
II
 for each of those lists. Since these 
disease categories are often phenotypically variable, many patients were run on more than one 
diagnostic list, which provided an opportunity to explore relationships between the clinical 
features and histories patients presented with, what lists they were run on, and which lists they 
tested positive for, if any. This information, combined with literature analysis, helped determine 
how the lists could be improved for clinical use, not only by adding new genes to each list, but 
also adjusting how the lists are structured and designed, which is important in determining which 
ones to use for a particular patient. We hypothesized that there were distinguishing clinical 
features that would help clinicians and researchers predict from which lists patients would most 
likely return positive results. The patients who did not return variants in known disease genes 
presented an opportunity for gene discovery – identifying rare, deleterious variants in new genes 
that could explain the disease phenotype. The ultimate goal of the study is to explore and 
                                                 
I
 A list of genes that have been found to be associated with that category of disease that also includes the pattern of 
inheritance and a tier based on the number of unrelated individuals in which disease-associated variants in that gene 
have been found 
II
 The likelihood that a test will provide the information needed to reach a diagnosis (i.e.: the proportion of patients 
run on each diagnostic list who received a (likely) positive result) 
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improve on how WES is used in NMDs, so the analysis of the positive results, curation of the 
lists, and research sweeps in the negative results was distilled into a framework to aid clinicians 
in determining when to use WES in patients with suspected NMDs. 
    
MATERIALS AND METHODS 
Whole Exome Sequencing and Variant Calling 
 A total of 83 patients were enrolled into the NCGENES neuromuscular, myopathy, or 
neuropathy cohorts after meetings with physicians and genetics counselors, and each patient was 
run on at least one of the NMD, myopathy, or neuropathy diagnostic lists (Supplemental 1.1-
1.2). The overall WES workflow and variant calling pipeline is illustrated in a schematic 
(Appendix 1.1). DNA was extracted from blood samples from the patients, and whole-exome 
sequencing was performed by NCGENES staff using the SureSelect
XT
 Target Enrichment 
System Kit for Illumina Multiplexed Sequencing (Appendix 1.2). Reads were stored and 
annotated in VarDb, an in-house variant database, based on variant frequency and predicted 
impact. An automated custom workflow developed by RENCI was used to return all variants in 
the 83 patients in genes on the diagnostic lists with a minor allele frequency (MAF) – the 
frequency at which the least abundant allele of a single nucleotide polymorphism (SNP) is 
present – in 1000 Genomes of less than five percent.  
Analysis of Diagnostic Yield and Positive Results 
 WES results were pulled from the database for each patient who had been run on at least 
one of the NMD, myopathy, or neuropathy diagnostic lists. These results took the form of a list, 
in which each patient received a “positive” if they were found to have a (likely) pathogenic or 
deleterious variant or variants, “negative” if they were not, and “uncertain” if they were found to 
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have a variant of unknown significance (VUS). The category of “uncertain” comprises multiple 
possibilities. First, there are VUS in which it is uncertain whether the variant is indeed 
deleterious. The second possibility arises from VUS that could possibly contribute to disease but 
are not wholly consistent with the patient’s phenotype. The third possibility is that the VUS is a 
heterozygous variant for a patient with a known recessive disorder, but a second variant was not 
found. Some patients received a “null” response, either indicating that their reported variants 
from WES had not yet been fully experimentally verified or that their findings were not yet 
recorded or updated. Diagnostic yields were calculated for the myopathy and neuropathy lists 
individually by dividing the number of patients who had received a positive result by the total 
number of patients who had been run on that list. For the patients who had been run on either 
both the myopathy and NMD lists or both the neuropathy and NMD lists, another diagnostic 
yield was calculated for the use of two lists in tandem (either myopathy and NMD or neuropathy 
and NMD) by dividing the number of patients who received a positive result on either list by the 
total number of patients who had been run on that combination of lists. Clinical information was 
pulled from REDCap for each patient who received a positive result from either combination of 
lists in order to compare the phenotype associated with the variant to the symptoms they 
displayed and their working clinical diagnosis.  
Curation of the Diagnostic Lists 
 The initial NCGENES diagnostic lists for myopathy, neuropathy, and NMDs were 
compared to determine the extent to which the lists shared genes. From examining the literature 
and consulting with physicians, it was decided that the NMD list should contain all the genes 
from both the neuropathy and myopathy lists, in addition to any genes associated with an NMD 
that is not a neuropathy or myopathy. Using the clinical reports and literature from the Online 
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Mendelian Inheritance in Man (OMIM) database, information about each gene that was unique 
to one of the three lists was collected, including gene function, disease phenotypes, known 
variants associated with disease, and clinical data about the patients in which the variants were 
found. Each gene unique to the NMD list was evaluated using information from the OMIM 
database in order to determine if any of those genes could be additionally classified as a 
myopathy or neuropathy gene. A gene was added to either the myopathy or neuropathy list if 
there was clinical evidence showing at least one patient with an associated phenotype 
demonstrating characteristics of myopathy or neuropathy. To ensure that the diagnostic lists were 
up-to-date, the OMIM clinical synopses were queried for all disease phenotypes associated with 
either myopathy or neuropathy, and every resulting entry was examined to ensure that there was 
at least one patient with that phenotype who demonstrated signs of a neuropathy or myopathy, 
such as an idiosyncratic nerve conduction study or muscle biopsy result. All genes associated 
with a disease phenotype that met those criteria on OMIM were added to the respective list, and 
all new myopathy or neuropathy genes were also added to the NMD list. The updated diagnostic 
lists were reexamined to determine the level of overlap among those genes in order to verify that 
the structure and content of the new lists would be appropriate for future variant calling when 
analyzing WES reads. 
Analysis of Negative Results 
 Using the initial NCGENES diagnostic lists, a research diagnostic (RDx) list of genes 
was generated from the in silico STRING database, which returned genes that encoded proteins 
that were known or predicted to interact with the proteins encoded by the myopathy, neuropathy, 
or NMD genes. This RDx list was used for gene discovery in the patients with negative 
diagnostic list results by computationally filtering their sequencing data and selecting for variants 
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in RDx genes. A frequency filter was applied to only obtain the variants in the patients with 
negative results with a MAF of less than one percent in the Exome Aggregation Consortium 
(ExAC) database, and the resulting variants were divided into truncating and missense variants. 
Each variant was manually curated in order to evaluate its potential pathogenicity. The 
parameters used to gauge pathogenicity were derived from reviewing literature examining best 
practices in characterizing WES variants and included the variant frequency across all 
NCGENES patients, the CADD scores, the MAF in ExAC, published gene and function 
information, and affected protein domains from UniProt. Clinical information from REDCap, 
such as family histories, symptoms, and previous testing, was used to assess inheritance patterns 
and narrow down the possible categories of NMDs. After manual curation of the negatives, the 
variants that passed each filter were collected for later confirmation and further characterization, 
and patients with interesting presentations and backgrounds were recorded for further, more in-
depth analysis. 
Guidelines for Use of Whole Exome Sequencing 
 The literature was perused to identify already existing clinical gene panels and to 
determine the relative advantages and disadvantages of WES compared to those panels. The 
information compiled in updating the gene lists was used to identify notable diagnostic features 
of different categories of NMDs, and this information was assembled into guidelines for the use 
of WES in patients with a suspected genetic NMD.    
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RESULTS 
Diagnostic Yields are Improved with the Use of Broader Lists in Tandem with Focused Lists in 
Neuromuscular Disease Cases 
In this cohort, a total of 32 patients were run on the myopathy diagnostic list and received 
a definitive response back, indicating either a (likely) pathogenic variant (positive), no 
pathogenic variant (negative), or a VUS (uncertain). Likewise, a total of 28 patients were run on 
the neuropathy diagnostic list and received a definitive result. When looking solely at the 
myopathy results, 27 patients were negative, 2 patients were uncertain, and 3 were positive, 
indicating a diagnostic yield of approximately 9%. For the neuropathy results, 23 patients were 
negative, 2 patients were uncertain, and 3 were positive, resulting in a diagnostic yield of 11%. 
Past analysis of NCGENES results have shown a roughly 12.7% diagnostic yield for patients 
enrolled in a neurological cohort, which includes NMD patients (Figure 2). More general data 
suggest that the diagnostic yield from WES is around 15-30%.
11
 
 
Figure 2. NCGENES diagnostic results and yields by disease category. 
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In this cohort, there were 23 patients who were run on both the myopathy and NMD lists, 
returning 4 positive, 3 uncertain, and 16 negative results. This resulted in a diagnostic yield of 
17%. Of the four patients who received a positive result, one of them tested positive on both lists, 
while the other three tested positive on the NMD list only. Of the patients who had VUS, two 
reported VUS in both lists, while the other had a VUS in the NMD list and was negative on the 
myopathy list. From examining the clinical information of the four patients who received 
positive results, in patient NCG_00473, the variant that was found was a likely pathogenic (LP) 
missense variant in MYH7, which is consistent with Laing distal myopathy. Previously, the 
patient was suspected of having a limb-girdle muscular dystrophy. Patient NCG_00044 was 
found to have a frameshifting variant in COL9A3 consistent with autosomal dominant multiple 
epiphyseal dysplasia 3, a skeletal disorder characterized by early-onset short stature, waddling 
gait, and pain in the knees and other joints
12
, providing a diagnosis when a significant amount of 
previous genetic testing had failed. NCG_00048 was found to have a pathogenic variant in 
GDAP1, which is associated with axonal Charcot-Marie-Tooth disease type 2K, a mild 
neuropathy phenotype.
13
 The patient previously was tested for SMN1 variants, leading to a 
diagnosis of a spinal muscular atrophy at age 3. Spinal muscular atrophies, which are 
characterized by degeneration of the anterior horn cells of the spinal cord, are the second most 
common lethal autosomal recessive disease in Caucasians, with the first being cystic fibrosis.
14
 
From the WES results, this patient received an updated diagnosis that overturned a long-standing 
previous one. Finally, NCG_00496 was diagnosed with a limb-girdle muscular dystrophy, and 
they were found to carry a homozygous frameshifting indel in ANO5, clarifying the specific type 
of limb-girdle muscular dystrophy. 
11 
  
There were 15 patients run on both the neuropathy and NMD lists, which returned 2 
positive results, 4 uncertain results, and 9 negative results, indicating a diagnostic yield of 13%. 
Of the two patients who received positive results, in both instances, the positives came from both 
the neuropathy and NMD lists. Of the four patients who were found to have VUS, in one 
instance, the VUS came from both lists, whereas in the other three instances, the VUS came from 
the NMD list.  
For both the myopathy and neuropathy cases, running the more specific list in tandem 
with the broader NMD list increased the diagnostic yield, though statistical significance was 
difficult to determine with the limited numbers. When the VUS results were considered in 
addition to the positive results, the increase in yield was greater. As comprehensive clinical 
information is not always available to the molecular analyst, a VUS result could be significant 
when subsequently analyzed by the ordering physician. Indeed, it may be warranted to further 
examine the VUS to clarify their effects, and cascade testing in affected family members is often 
performed. Regardless, for both combinations of lists, the positive and uncertain results 
predominantly came from the broader NMD list. The diagnostic yield data and interesting 
positive cases for the combined myopathy and NMD list are summarized in Figure 3 and Table 
1, respectively. 
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Figure 3. Diagnostic yields for NCGENES patients when run on only the neuropathy list (upper-left), only the 
myopathy list (upper-right), both the myopathy and NMD list (bottom left), and both the neuropathy and NMD list 
(bottom right). 
 
ID Working Clinical 
Diagnosis 
Previous Genetic 
Testing 
Positive or Likely 
Result 
Clarification of 
Diagnosis 
NCG_00473 Suspected LGMD Unknown MYH7 MS LP 
consistent with 
Laing distal 
myopathy  
Clarified diagnosis 
NCG_00044  EDS I, II, IV; MYOT 
(LGMD 1a); Ullrich 
MD; LGMD 1B & 
C; FSHD 
COL9A3 frameshift 
for AD MED3 
Provided diagnosis 
NCG_00048 Spinal muscular 
atrophy diagnosis at 
age 3 
SMN1 Pathogenic variant 
in GDAP1 – 
CMT2K disease 
Changed diagnosis 
NCG_00496 
 
Suspected LGMD 
 
FKRP, DMD, FSHD 
 
Homozygous ANO5 
frameshift indel for 
AR LGMD type 2L 
Clarified diagnosis 
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Table 1. Clinical information of patients who received positive results from the combined myopathy and NMD lists. 
Italicized terms are gene names. Working Clinical Diagnosis: LGMD = limb-girdle muscular dystrophy. Previous 
Genetic Testing: EDS = Ehlers-Danlos syndrome, MD = muscular dystrophy, FSHD = facioscapulohumeral 
muscular dystrophy, DMD = Duchenne muscular dystrophy. Positive or Likely Result: MS = missense, LP = likely 
pathogenic, AD = autosomal dominant, MED3 = multiple epiphyseal dysplasia 3, CMT2K = Charcot-Marie-Tooth 
type 2K, AR = autosomal recessive. 
 
Analysis of Negative Results Reveals a Potential Patient for an In-Depth Research Sweep 
 Neuromuscular disorders are an extremely broad category of inherited diseases that have 
a variety of inheritance patterns, including autosomal dominant or recessive. Consider the case of 
a causal variant that has either an autosomal dominant or autosomal recessive mode of 
inheritance. In the simplest case of the Hardy-Weinberg equilibrium of a single locus with two 
alleles with frequencies p and q, the equation is 
𝑝2 + 2𝑝𝑞 + 𝑞2 = 1, 
where 𝑝 is the frequency of the major allele and 𝑞 is the frequency of the minor allele.  
Assuming q is the frequency of the causal variant and the mode of inheritance is autosomal 
recessive, the expected overall prevalence of NMDs in the population based on the frequency of 
the causal variant would be 1:
1
𝑞2
. Given the overall prevalence of NMDs, 
1
𝑞2
 must be greater than 
at least 3,500.
1,2
 So, q should have a frequency of at most 0.016, as 
1
0.0162
=
1
2.56∗10−4
= 3906.25, 
resulting in a calculated overall prevalence of 1 in 3,900. However, the initial frequency filter 
used to extract variants from the negative patient WES data was a minor allele frequency (MAF) 
of less than one percent from the Exome Aggregation Consortium (ExAC) database. This 
calculated frequency q is greater than the initial frequency limit applied to extract variants in the 
first place, so it would be too lenient to further filter the results. Assuming that the causal variant 
is inherited in an autosomal dominant fashion, the overall expected population prevalence of 
NMDs would be 1:
1
2𝑝𝑞+𝑞2
. A reasonable value of q would then be dependent on the value of p. 
14 
  
Given that the initial frequency filter retrieved variants with an ExAC frequency of less than 1%, 
it would not be unreasonable to assume that p should have a frequency of at least 0.99. If that 
assumption is accepted, then a simple calculation using the quadratic formula shows that q 
should not exceed approximately 0.00014, which would give an overall prevalence of 1 in 3,600. 
These calculations assumed the overall prevalence of NMDs was around 1 in 3,500 (assuming 
the 1 in 3,000 prevalence would have allowed for higher MAF cutoffs, which is counterintuitive 
to further filtering variants). Given that the most common group of neuromuscular diseases – the 
Charcot-Marie-Tooth diseases or hereditary peripheral neuropathies – have an overall prevalence 
of roughly 1 in 2,500
15
, setting the upper limit for q at 0.00014 appears reasonable. The overall 
prevalence is dominated by the more well-known (i.e.: more common) conditions, and if any 
patient truly has a “new” or “undiscovered” NMD, it would be expected to be rare. So, the upper 
limit for the MAF was determined to be 0.00014. 
To identify a rare variant in a gene that could explain a particular disease phenotype, that 
variant should only appear in the patients with the disease and not in patients with unrelated 
illnesses. Frequencies were thus the primary and most important filter. When the initial 
frequency filter (only accepting variants with a MAF of less than one percent in ExAC) and the 
RDx list were applied to the WES data for patients who had received negative results, there were 
4 truncating variants and 189 missense variants remaining within the cohort.  All four truncating 
variants were rare enough to pass the subsequent limit set on the MAF, but in the process of 
examining the clinical notes on REDCap, it was found that three of the four patients were later 
found to have tested positive for variants in genes associated with an NMD that were not on the 
current diagnostic list. The remaining patient, NCG_00481, was found to be a promising 
candidate for a research sweep to specifically mine through all of their variants. This patient had 
15 
  
received mitochondrial genome sequencing, which was negative, and their microarray results 
were inconclusive. From the family history, the older brother had previously passed away of a 
similar suspected neuromuscular disorder, and there was a definite family history of symptoms 
on the maternal side, including hyperflexibility, myopathic features, and patchy mitochondrial 
swelling. This family history suggests something being inherited in an autosomal dominant 
manner. Taken together with the negative results from mitochondrial genome sequencing and 
WES, NCG_00481 would be a good candidate for further in-depth analysis by research sweeps. 
For the missense variants, applying the MAF filter of 0.00014 reduced the number of 
variants from 189 to 85. Next, the Combined Annotation Dependent Deletion (CADD) score, a 
broad metric that integrates factors such as allelic diversity and experimentally-measured 
regulatory effects to score the deleteriousness of SNPs and indels, was examined. Typically, the 
standard in the discipline is to call variants with a score of 13 or greater to be considered 
deleterious. Applying this CADD filter then reduced the number of variants to 54. Each variant 
was inspected using the UCSC Genome Browser in order to check whether the variant was in a 
repetitive region, which would increase the likelihood of the variant being the result of 
sequencing miscalls or a sequencing artifact. Following inspection by the UCSC Genome 
Browser, the variants were examined for affected protein domains from UniProt and for 
published gene information and function from OMIM and GeneCards. This sweep has not yet 
identified a sufficiently rare variant with a plausible mechanism for contributing to an NMD, but 
those variants will still be retained for analysis by more sophisticated methods. 
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Curation of the Diagnostic Lists Adds Many More Genes and Changes the Structure of the Lists 
to Improve Clinical Use 
Based on evaluations of the literature
2,3
, which categorized myopathies and neuropathies 
under the broad umbrella of NMDs, it was decided that the NMD list should encompass all genes 
on the myopathy and neuropathy lists in addition to any potentially unique genes. This list 
structure would make the NMD list a broad-spectrum solution or method of analysis, which 
could be applied if the patient did not present with recognizable features of neuropathies or 
myopathies. For WES to be a useful research and diagnostic tool, the genes associated with the 
disorders of interest must be known, so the diagnostic lists must be continually updated to match 
new findings. 
The initial lists were analyzed to examine the extent of gene overlap (numerical summary 
shown in Figure 4). Of the 80 genes on the neuropathy diagnostic list, all but 8 of them were also 
contained in the NMD diagnostic list. Likewise, 70 of the 99 genes on the myopathy diagnostic 
list were contained within the NMD diagnostic list. Of the 316 genes on the NMD diagnostic list, 
177 were found solely on the NMD list. Each of these 177 genes was subsequently examined 
using the literature found on OMIM to see if it could also be classified as either a myopathy or a 
neuropathy gene. In total, 28 of those 177 genes were added to the myopathy list, and 18 were 
added to the neuropathy list. The summary of this survey of the literature, which reports the 
gene, the list it was added to, and the associated phenotypes, is displayed in Appendix 2. 
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Figure 4. Distribution of genes among the three diagnostic lists. There is no overlap between the myopathy and 
neuropathy lists, and the NMD list encompasses large portions of both the neuropathy and myopathy lists.  
 
 In surveying the OMIM database of clinical synopses and phenotypes, 80 new genes 
were added to the myopathy list and 118 genes were added to the neuropathy list. In accordance 
with the decision made about the structure of the lists, all genes added to the myopathy and 
neuropathy lists were also added to the NMD list. In total, the NMD list expanded by 165 new 
genes, which reflected the fact that some of the genes added to the myopathy and neuropathy 
lists were already on the NMD list. The three new diagnostic lists were reexamined to determine 
the level of overlap, with a numerical summary shown in Figure 5. The organization of these 
three news lists matched our expectations, with the NMD list encompassing all of the neuropathy 
and myopathy lists, and the myopathy and neuropathy lists being largely unique individuals. The 
updated diagnostic lists for myopathy, neuropathy, and NMDs lists are displayed as tables in 
Supplemental 2.  
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Figure 5. Distribution of genes among the three diagnostic lists after addition of new genes discovered through 
manual surveys of the literature. 
 
Guidelines for Incorporating WES into a Clinical Workflow for Patients with Suspected 
Neuromuscular Disorders 
 We hypothesized that knowledge of any distinguishing features of types of NMDs would 
narrow down the possible genes that could contain a causal variant, improving the efficiency of 
analyzing WES data and improving the likelihood that a patient would get a positive result. WES 
typically has good coverage of approximately 85%-90% of the exons in the genome, leaving 
inadequate coverage for about 1,000 to 2,000 genes.
5,16
 As a result, negative and uncertain results 
should not be taken as an absolute rejection. This emphasizes the importance of clinical 
phenotypic information in analyzing WES output, so knowledge of characteristic features for 
different types of NMDs would be beneficial for the physician in selecting an appropriate genetic 
test (which may or may not include WES) and for the molecular analyst in identifying and 
verifying causal variants. Curating the literature
17
 has identified several clinical features often 
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indicative of a congenital myopathy, as well as distinguishing muscle biopsy features, which are 
summarized in Tables 2.1-2.2. These features were often found to be particular to a specific 
genetic diagnosis, but considering that the aim of the study is to aid the clinician in the use of 
WES, I considered it more reasonable to provide the clinician with categories of details to look 
for so that they would be able to provide more detailed information to the molecular analyst, 
improving the efficiency and confidence of variant calling. 
Clinical Feature Age Range 
Facial weakness  
Opthalmoplegia (extraocular muscle weakness) 
Ptosis (drooping of eyelids) 
Facial dysmorphisms (long face or head relative to 
width, high arched palate)  
Bulbar weakness (sucking or swallowing) 
Significant respiratory involvement at birth Newborns and children less than 2 years 
Severe congenital hypotonia (“floppy infant”) 
Predominant axial hypotonia  
Orthopedic deformities 
Dislocation of hip 
Club feet 
Fetal akinesia or severe arthrogryposis (joint 
contracture) 
Scoliosis  
Rigid spine 
Cardiomyopathy Older children from 2 years to adolescence  
Foot drop/pes cavus 
Malignant hyperthermia  
Respiratory and axial involvement disproportionate to 
skeletal muscle weakness 
 
Table 2.1 Clinical features found to be suggestive of a congenital myopathy, divided by age ranges where those 
features might be most useful in a diagnostic context. 
 
Structural Defect Description 
Rods Cytoplasmic and occasionally intranuclear bodies indicative of nemaline 
myopathies; Rod-like or ovoid, with or without attached filaments; Variable in 
distribution and number; Stained red by Gomori trichrome technique; Electron 
microscopy reveals lattice structure similar to Z-line; Immunohistochemistry 
reveals proteins similar to Z lines, especially α-actinin 
 
Cores Variable appearance, but classically devoid of mitochondria and therefore oxidative 
enzyme activity; May be peripheral or central; May be multiple per fiber; Extends 
down a significant length of the fibers 
 
Central nuclei Large bodies that are spaced at intervals down the fiber and occupy large volumes 
of the fiber; Number of nuclei may increase with age; In neonates, often associated 
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with dark stained centers that have a pale peripheral halo with oxidative enzyme 
staining 
 
Caps Peripheral, well-demarcated areas eosinophilic with a haematoxylin and eosin 
stain; No ATPase activity and myosin staining; Positively label for actin and α-
actinin; Electron microscopy shows focal, peripheral areas of myofilaments 
oriented in multiple directions, usually with attached thin filaments and thickened 
Z-lines 
 
Minicores Multiple focal areas devoid of oxidative enzyme activity, and appear as such in 
longitudinal sections; Electron microscopy is a useful tool for identifying focal 
areas of myofibrillar disruption 
 
Hyaline bodies Focal areas that are seen as granular, basophilic zones with a haematoxylin and 
eosin stain; Positive for ATPase activity and demonstrate slow myosin staining; 
Electron microscopy shows them as granular areas 
 
Necklace fibers Feature a clear ring or loop of oxidative enzyme staining internally within the fiber 
and not attached to the sarcolemma  
 
 
Table 2.2 Pathological muscle biopsy features found to be suggestive of a congenital myopathy. 
 
Like the inherited myopathies, the inherited neuropathies can be very broadly divided 
into those in which the neuropathy is the primary part of the disease and those in which the 
neuropathy is part of a more generalized, often multisystem disorder (i.e.: a syndromic 
neuropathy.) As a result, I classified some of the distinguishing characteristics of inherited 
neuropathies into broad categories and related them to some disease phenotypes. The literature 
findings
17-20
 of these categories are summarized in Table 3. 
Clinical Feature Associated Phenotypes 
Uniform slowing of nerve 
conduction velocities 
Charcot-Marie-Tooth 1 (demyelinating - motor conduction velocities of the median 
or ulnar nerve less than 38 m/s); Dejerine-Sottas disease; metachromatic 
leukodystrophy; Krabbe’s disease; Cockayne’s disease  
 
Asymmetric or multifocal 
slowing of nerve conduction 
velocities 
Charcot-Marie-Tooth X-linked; Refsum’s disease; Pelizeus-Merzbacher disease; 
adrenomyeloneuropathy 
 
 
Sensory dysfunction 
(auditory and visual, of limbs, 
etc.) 
Hereditary sensory and autonomic neuropathies; familial amyloid 
polyneuropathies; neuropathies associated with mitochondrial disorders; autosomal 
dominant Charcot-Marie-Tooth (axonal); autosomal recessive Charcot-Marie-Tooth 
 
Distal limb involvement Autosomal dominant Charcot-Marie-Tooth 1; peripheral neuropathies; distal 
hereditary motor neuropathies (muscle weakness, but typically no sensory loss); 
hereditary sensory and autonomic neuropathies 
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Proximal limb involvement Autosomal recessive Charcot-Marie-Tooth; peripheral neuropathies 
 
 
Table 3. Groups of clinical features suggestive of neuropathies, with some associated phenotypes. Due to the 
phenotypic heterogeneity of inherited neuropathies, these categories of symptoms may be found in other 
neuropathies or NMDs, but they are often key signs of a neuropathy phenotype. 
 
 These features provide clinical evidence of a particular disease phenotype, but the 
importance of accurate genetic diagnosis cannot be overstated. Therefore, the clinician must 
make a decision about the appropriate testing to use. While WES has been proven to be a 
powerful diagnostic approach, there are limitations that include a large list of generated variants, 
incomplete coverage with capture libraries, and difficulty detecting variants resulting from repeat 
expansion, copy-number variation, epigenetic alterations, and some others (Table 4).
1,9,21
 
Therefore, WES would not be the test of choice for diseases associated with these types of 
variants or that have existing clinical panels that cover a large majority of the known genes. In 
these cases, WES would either not be able to detect causal variants, or another clinical panel 
could be used to return results for less cost or in less time. I found GeneTests 
(www.genetests.org) to be an excellent up-to-date resource for finding the availability and cost 
of genetic testing in both diagnostic and research laboratories, and a summary of some available 
tests for NMDs is included in Table 5.  Based on gene information, availability of testing, and 
clinical symptoms, we devised a decision-making tool for incorporating WES in a clinical setting 
for patients with suspected neuromuscular disease (Appendix 3).  
Variant Type Associated Phenotypes 
Repetitive DNA (including 
trinucleotide repeats) 
Fragile X syndrome, Huntington’s disease, myotonic dystrophy 2, X-
linked spinal and bulbar muscular atrophy, oculopharyngeal 
muscular dystrophy 
 
Copy-number variants DiGeorge syndrome (22q11.2 deletion syndrome), Charcot-Marie-
Tooth disease type 1, facioscapulohumeral muscular dystrophy 
 
Structural variants (including 
chromosomal translocations and 
inversions; large deletions, 
Duchenne/Becker muscular dystrophy, spinal muscular atrophy 1 
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duplications, and rearrangements) 
 
Long indel variants Resistance to HIV infection 
 
Aneuploidy Down’s syndrome, Turner syndrome 
 
Epigenetic alterations Prader-Willi syndrome, Beckwith-Wiedemann syndrome 
 
   
Table 4. Variant types currently not well-detected or undetected by exome sequencing, with examples of associated 
phenotypes. NMD phenotypes are written in bold. 
 
Disorders Laboratory Method Genes Tested Turnaround 
Time and 
Cost 
NMDs Emory Molecular 
Genetics 
Laboratory 
N/A  
ACTA1, AMPD1, AMPD3, ANO5, CAPN3, 
CAV3, COL6A1, COL6A2, COL6A3, DES, 
DMD, DYSF, EMD, FKRP, FKTN, GAA, GNE, 
ISPD, ITGA7, LAMA2, LARGE, LMNA, 
MYOT, NEB, PLEC, PMM2, POMGNT1, 
POMT1, POMT2, PYGM, RYR1, RYR2, 
SEPN1, SGCA, SGCB, SGCD, SGCE, SGCG, 
SIL1, TCAP, TNNI2, TNNT1, TPM2, TPM3, 
TRIM32, TTN 
 
12-13 weeks; 
Contact lab 
NMDs GeneDx NGS, Deletion 
and duplication 
(copy-number 
variation) 
 
ACTA1, ANO5, ATP2A1, B3GALNT2, BAG3, 
BIN1, CACNA1S, CAPN3, CAV3, CFL2, 
CHKB, CLCN1, CNTN1, COL6A1, COL6A2, 
COL6A3, CRYAB, DAG1, DES, DMD, 
DNAJB6, DNM2, DPM1, DPM2, DPM3, 
DYNC1H1, DYSF, EMD, FHL1, FKRP, FKTN, 
FLCN, GAA, GMPPB, GNE, IGHMBP2, ISPD, 
ITGA7, KBTBD13, KLHL40, LAMA2, LAMP2, 
LARGE, LDB3, LMNA, MEGF10, MTM1, 
MYH7, MYOT, NEB, PLEC, PLEKHG5, 
POMGNT1, POMT1, POMT2, RYR1, SCN4A, 
SEPN1, SGCA, SGCB, SGCD, SGCG, SIL1, 
SYNE1, TCAP, TMEM5, TNNI2, TNNT1, 
TNPO3, TPM2, TPM3, TRIM32, TRPV4, TTN, 
UBA1, VRK1 
 
8-9 weeks; 
Contact lab 
Congenital 
myopathies 
PreventionGenetics NGS  
ACTA1, BIN1, CCDC78, CFL2, CNTN1, 
DNM2, KBTBD13, KLHL40, KLHL41, MTM1, 
MYF6, MYH7, NEB, RYR1, SEPN1, STAC3, 
TNNT1, TPM2, TPM3 
 
4-6 weeks; 
$2,590.00 
Congenital 
myopathies 
and 
muscular 
dystrophies 
GeneDx NGS, Deletion 
and duplication 
(copy-number 
variation) 
 
ACTA1, CFL2, CHKB, COL6A1, COL6A2, 
COL6A3, FKRP, FKTN, ITGA7, KBTBD13, 
LAMA2, LMNA, MEGF10, NEB, RYR1, 
SEPN1, SYNE1, TNNT1, TPM2, TPM3 
 
8-9 weeks; 
Contact lab 
Charcot-
Marie-Tooth 
(Full Panel) 
Invitae NGS, Deletion 
and duplication 
(copy-number 
variation) 
 
AARS, BSCL2, DNM2, EGR2, FGD4, FIG4, 
GARS, GDAP1, GJB1, HSPB1, HSPB8, KIF1B, 
LITAF, LMNA, MED25, MFN2, MPZ, MTMR2, 
NDRG1, NEFL, PMP22, PRPS1, PRX, RAB7A, 
SBF2, SH3TC2, TRPV4, YARS 
 
2-3 weeks; 
$1,500.00 
Hereditary 
neuropathies 
Emory Molecular 
Genetics 
Laboratory 
N/A  
ADCK3, ALDH3A2, APTX, ATL1, ATM, 
C10orf2, CACNB4, CTDP1, DCTN1, DNM2, 
EGR2, FGD4, FGF14, FXN, GAN, GARS, 
12-13 weeks; 
Contact lab 
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GDAP1, GJB1, HOXD10, HSPB1, HSPB8, 
IKBKAP, ITPR1, KCNA1, KCNC3, KIAA0196, 
KIF1B, KIF5A, L1CAM, LITAF, MFN2, MPZ, 
MRE11A, MTMR2, MTTP, NDRG1, NEFL, 
NGF, NIPA1, PEX7, PHYH, PLP1, PMP22, 
PNPLA6, POLG, PRKCG, PRPS1, PRX, 
RAB7A, REEP1, SACS, SBF2, SH3TC2, SIL1, 
SLC12A6, SLC1A3, SPAST, SPG11, SPG20, 
SPG21, SPG7, SPTBN2, SPTLC1, TDP1, 
TTBK2, TTPA, WNK1, YARS, ZFYVE26, 
ZFYVE27 
 
 
Table 5. Some genetic panels available for neuromuscular disorders, with the tested disorders, covered genes, 
turnaround time, lab location, and cost. Information taken from GeneTests (www.genetests.org).  
 
DISCUSSION 
 Since its inception, whole exome sequencing and indeed, massively parallel sequencing 
strategies as a whole, have proven to be very powerful in identifying causal variants in disease. 
However, as with any new technology, time and effort must be dedicated to ensure proper 
implementation and best practices. The objective of this study then, was to tackle the question of 
what must be done to make the most use of whole exome sequencing in patients with 
neuromuscular disorders, a broad and heterogeneous group. Though this study is preliminary, the 
analysis has identified several points that will be important in guiding the use of WES for this 
unique and diverse subset of patients. 
 First and foremost is the importance of making sure that the diagnostic lists are as 
complete and up-to-date as possible. WES of human samples that have 100x or more coverage 
(the average number of reads representing a given nucleotide in the reconstructed sequence) 
generate around 20,000-30,000 single nucleotide variants (SNV) and indel calls, according to 
some estimates.
23
 The diagnostic list is a method to prioritize variants that are relevant to the 
disease, by allowing the analyst to consider only those variants present in known disease genes. 
The lists are also important for identifying potentially novel disease variants. For example, a 
novel rare non-synonymous SNV found in a gene known to cause a phenotype is more likely to 
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prove to be causative as well.
5
 Discovering new disease variants or genes also better illustrates 
genetic functions and pathways by providing an opportunity to investigate deviations from 
normal activity. In light of just how much the diagnostic lists were expanded, it may be more 
fruitful to wait for the results of a reanalysis of the WES data before further attempting to 
identify novel disease genes or variants. So, a significant amount of time and effort was spent 
scouring the literature to both add new known disease genes to the lists and to ensure that the 
genes already on the list were accurate. Curating the lists to ensure they stay current is a task that 
must be continuously done, as more information is constantly discovered about variants that 
supports or rejects its role in disease. 
 A major challenge of implementing WES in a clinical environment is determining which 
patients, and which diseases, are most amenable to diagnosis using this method. As such, 
assessing the diagnostic yield, or how often patients receive a result that can explain their 
phenotype, is paramount to addressing this obstacle. It is clear, both from the literature and 
previous NCGENES data, that the diagnostic yield varies for different genetic conditions. Data 
from NCGENES indicates a past 12-13% yield in patients with neurological conditions, while 
literature values suggest an overall diagnostic yield of 15-30%
11,24,25
, and some evidence 
suggesting a yield of around 20-30% for neurological disorders.
25
 As shown, the diagnostic 
yields we obtained for our neuropathy, neuromuscular, and NMD patients was lower than those 
values, but those results are likely understated. First is the matter of the VUS, which as defined, 
could actually contribute to the disease phenotype. While speculative, if the VUS was a 
heterozygous variant, it could be possible that the patient’s phenotype has an oligogenic mode of 
inheritance, so there could be another heterozygous variant in a different, though functionally-
related, gene, and together, they result in the patient’s phenotype. A probably more realistic 
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explanation is that the VUS simply should be further characterized to try to ascertain its 
deleteriousness. Second, and more obvious, is the fact that the initial prioritization of variants 
was incomplete because the diagnostic lists used to streamline the variant search were 
incomplete. Evaluation of the literature doubled the size of the myopathy and neuropathy lists 
and increased the size of the NMD list by 50%. Most likely, a reanalysis of those patients’ WES 
data using the new lists to cultivate the variant search will result in significantly higher 
diagnostic yields, and this analysis is ongoing. 
 Another question related to the use of the diagnostic lists is deciding which lists should 
be applied in the variant search. This is largely a classic question of efficiency, for a broader 
diagnostic list would be more likely to return positive variants at the cost of time, effort, and 
computational power. The initial data analyzed here is perhaps too limited in scale to make broad 
assertions (though that is usually a problem when dealing with rare diseases), but the information 
gleaned from the literature combined with the data gives us at least some confidence. We found 
that patients who were run on the broad NMD list in tandem with a more focused list had greater 
diagnostic yields, and their positive results tended to come from the broad lists. This combination 
of lists also returned more VUS (which again, typically came from the NMD list), which could 
warrant further characterization and lead to a deleterious variant that explains that phenotype. 
Now consider the four positive cases in the combination myopathy/NMD list. Each of those 
patients had either no or inconclusive testing in the past, limiting the amount of information 
available in the present to build off of for a diagnosis. Even so, WES was able to provide them 
with a (clarified) diagnosis or even change an old one. In addition, analysis of the literature has 
indicated several clinical features and neuromuscular examination results that are predictive of a 
specific genetic diagnosis while at the same time emphasizing the need for genetic testing in 
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order to confirm it. It is, as they say, the only way to be sure. So, these findings at least suggest 
that when patients do not present with indicative symptoms (especially muscle or nerve biopsy 
and nerve conduction velocity results), it is advantageous to use the broader, more encompassing 
diagnostic gene list. The method of construction of the updated myopathy, neuropathy, and 
NMD lists, in which the NMD list encompasses all myopathy and neuropathy genes while also 
containing its own unique genes, reflects this philosophy. I anticipate that reanalyzing the 
patients using the updated diagnostic lists will not only return more positive results, it will also 
provide more of our own empirical data to connect certain symptoms, test results, or family 
histories to a particular genetic diagnosis.  
 The ultimate goal of this study, and a major goal of NCGENES as a whole, is to establish 
evidence-based guidelines for the use of whole exome sequencing for diagnosis. Based on the 
analysis of the diagnostic yields and the work done to curate the lists, it seems our framework is 
a reasonable one. WES is currently indicated for detection of rare variants in patients with a 
suspected highly-penetrant Mendelian disorder, after traditional single-gene diagnostic methods 
have not resulted in a diagnosis or multigene approaches would be too expensive.
9
 Our 
framework reflects that, calling for the use of WES in situations where the cost or technical 
limitations would not prohibit it. If a clinical panel already exists, the sequencing coverage of the 
panel compared to WES is a key consideration. For medical diagnosis, a mean depth of coverage 
of 100x or more is desirable, as it greatly reduces the difficulty in identifying and filtering out 
false positive variant calls.
5
 If, for example, there are 20,000-30,000 variant calls
23
, even a 1% 
false positive rate introduces hundreds of false calls, complicating diagnostic applications. 
Typically, WES platforms have 50x coverage, though this can be pushed up to 100x. Clinical 
gene panels are almost guaranteed to have significantly higher coverage, so it is advantageous in 
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terms of cost, analysis workload, and accuracy to use a clinical panel if one that covers enough 
genes exists. Especially important in this framework is what the clinician needs to report when 
submitting samples for WES. By essentially being as detailed as possible about clinical findings, 
family histories, and test results, the clinician provides important information that improves the 
confidence of variant calling and analysis. Future steps that would improve these guidelines 
would include using the reanalyzed patient data to provide a statistical analysis of the predictive 
power of different clinical items towards a specific genetic diagnosis and providing a more in-
depth cost and coverage analysis of available clinical panels compared to WES.  
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APPENDIX 1: NCGENES WHOLE-EXOME SEQUENCING WORKFLOW 
 
 
Appendix 1.1. The WES workflow and variant calling pipeline for NCGENES. The library preparation and 
sequencing steps are further detailed in Appendix 1.2. The sequencing done is paired-end sequencing. When the 
variants are called, they are given a designation based on their predicted or known pathogenicity. The “A” 
designation is for variants that are known to cause disease. Designations “B” through “F” are in descending order of 
predicted pathogenicity. The smaller the allele frequency and the more potentially disruptive a variant is, the higher 
it is ranked and the more likely it is to be pathogenic. 
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Appendix 1.2. The overall sequencing library preparation workflow for the SureSelect
XT
 Target Enrichment System 
Kit for Illumina Multiplexed Sequencing. Paired-end sequencing is used. 
 
APPENDIX 2: CURATION OF THE NEUROMUSCULAR DISEASE DIAGNOSTIC 
LIST 
  
Genes Added to the Myopathy List Genes Added to the Neuropathy List 
Gene Name 
(HGNC) 
Disease Phenotype Gene Name 
(HGNC) 
Disease Phenotype 
FXN Friedrich ataxia (with or without retained 
reflexes) 
FXN Friedrich ataxia (with or without retained 
reflexes) 
MYH14 Autosomal dominant deafness 4A; Peripheral 
neuropathy, myopathy, hoarseness, and 
hearing loss 
MYH14 Autosomal dominant deafness 4A; 
Peripheral neuropathy, myopathy, 
hoarseness, and hearing loss 
TTPA Ataxia (Friedrich-like) with isolated vitamin 
E deficiency 
TTPA Ataxia (Friedrich-like) with isolated 
vitamin E deficiency 
ABHD5 Chanarin-Dorfman syndrome GJC2 
 
AR spastic paraplegia 44; Hereditary 
lymphedema 1C; Hypomyelinating 
leukodystrophy 2 
CCDC78 
Centronuclear myopathy 4 
 
INF2 Dominant intermediate Charcot-Marie-
Tooth E; Glomerulosclerosis, focal 
segmental 5 
COL6A1 
Bethlem myopathy; Ullrich congenital 
muscular dystrophy LRSAM1 
Axonal Charcot-Marie-Tooth 2P 
COL6A2 
Bethlem myopathy; Ullrich congenital 
muscular dystrophy; congenital myosclerosis  NF1 
Neurofibromatosis type 1 
COL6A3 
Bethlem myopathy; Ullrich congenital 
muscular dystrophy PDSS1 
Primary coenzyme deficiency 2 
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COL9A3 
Multiple epiphyseal dysplasia 3; Multiple 
epiphyseal dysplasia with myopathy PDYN 
Spinocerebellar ataxia 23 
DYSF 
Miyoshi muscular dystrophy 1; Limb-girdle 
muscular dystrophy type 2B; Distal 
myopathy with anterior tibial onset REEP1 
Autosomal dominant spastic paraplegia 31; 
Distal hereditary motor neuronopathy type 
VB 
FKBP14 
Ehlers-Danlos syndrome with progressive 
kyphoscoliosis, myopathy, and hearing loss SCN4A 
Paramyotonia congenita, Congenital 
myotonia (acetazolamide-responsive); 
Acetazolamide-responsive myasthenic 
syndrome; Hyper and hypokalemic 
periodic paralysis 
FKRP 
Muscular dystrophy-dystroglycanopathy 
(congenital with brain and eye anomalies; 
congenital with or without mental 
retardation; limb-girdle)  SETX 
Juvenile amyotrophic lateral sclerosis 4; 
Autosomal recessive spinocerebellar ataxia 
1 
FLNC Distal myopathy 4; Myofibrillar myopathy 5  SPG11 Autosomal recessive spastic paraplegia 1 
LDB3 
Dilated cardiomyopathy 1C; Left Ventricular 
noncompaction 3, with or without dilated 
cardiomyopathy; Myofibrillar myopathy 4 SPTLC2 
Hereditary sensory and autonomic 
neuropathy, type IC 
MEGF10 
 
TRPV4 
Brachyolima type 3; Familial digital 
arthropathy-brachydactyly; Hereditary 
motor and sensory neuropathy type IIc; 
Metatropic dysplasia; Parastremmatic 
dwarfism; Scapuloperoneal spinal 
muscular atrophy; Spondyloepiphyseal 
dysplasia Maroteaux type; Distal 
congenital nonprogressive spinal muscular 
atrophy; Kozlowski type 
spondylometaphyseal dysplasia 
Myopathy, areflexia, respiratory distress, and 
dysphagia (early onset) 
 
 
MTMR14 
Modifier of autosomal centronuclear 
myopathy TUBB3 
Congenital fibrosis of extraocular muscles 
type 3A; Complex cortical dysplasia 
MTTP 
Myopathy; Merff syndrome; Susceptibility to 
Parkinson disease ZFYVE26 
Autosomal recessive spastic paraplegia 15 
MYBPC3 
Dilated cardiomyopathy 1MM; Familial 
hypertrophic cardiomyopathy 4; Left 
ventricular noncompaction 10 IGHMBP2 
Axonal Charcot-Marie-Tooth 2S; Distal 
hereditary motor neuronopathy type VI 
MYF6 Centronuclear myopathy 3 
 
MYH3 Distal arthrogryposis type 2A and 2B 
NEB Autosomal recessive nemaline myopathy 2 
PLEC 
Epidermolysis bullosa simplex (Ogna type; 
with pyloric atresia; with epidermolysis 
bullosa simplex); Limb-girdle muscular 
dystrophy type 2Q 
SGCD 
Dilated cardiomyopathy 1L; Limb-girdle 
muscular dystrophy type 2F 
SIL1 Marinesco-Sjorgen syndrome  
TCAP 
Limb-girdle muscular dystrophy type 2G; 
Dilated cardiomyopathy 1N 
TNNT3 Distal arthrogryposis type 2B  
TPM2 
CAP myopathy; Autosomal dominant 
nemaline myopathy 4; Distal arthrogryposis 
type 2B; Distal arthrogryposis multiplex 
congenita type 1 
VCP 
Amyotrophic lateral sclerosis 14 with or 
without frontotemporal dementia; Inclusion 
body myopathy with early-onset Paget 
disease and frontotemporal dementia  
 
Appendix 2. Genes on the NMD diagnostic list that were added to the myopathy or neuropathy lists upon inspection 
using the OMIM database. Many genes were associated with more than one disease phenotype, but not all of those 
disease phenotypes were associated with a neuropathy or myopathy. 
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APPENDIX 3: INCORPORATING WHOLE EXOME SEQUENCING INTO A 
CLINICAL SETTING FOR PATIENTS WITH NEUROMUSCULAR DISEASE 
 
Appendix 3. A possible method of incorporating whole exome sequencing (WES) in a clinical setting for patients 
with suspected neuromuscular disease. 
 
SUPPLEMENTAL MATERIALS 
Supplemental materials have been included with this submission as additional PDF files. 
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